Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Journal of Thrombosis and Haemostasis : JTH|October 10, 2007
Development of sandwich-type ELISAs for the quantification of rat and murine thrombin activatable fibrinolysis inhibitor in plasmaK Hillmayer, E Brouwers, F León-Tamariz, et al.
The Journal of Biological Chemistry|September 18, 2001
The distal hinge of the reactive site loop and its proximity: a target to modulate plasminogen activator inhibitor-1 activityA P Bijnens, A Gils, J M Stassen, et al.
Journal of Thrombosis and Haemostasis : JTH|September 3, 2011
TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformationM L V Hendrickx, A DE Winter, K Buelens, et al.
Journal of Thrombosis and Haemostasis : JTH|August 24, 2017
Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm diseaseK I Bridge, L Bollen, J Zhong, et al.
Alimentary Pharmacology & Therapeutics|December 12, 2017
Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical responseE Dreesen, T Van Stappen, V Ballet, et al.
Journal of Thrombosis and Haemostasis : JTH|October 6, 2017
Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in miceC Tersteeg, B S Joly, A Gils, et al.
Journal of Thrombosis and Haemostasis : JTH|November 21, 2007
Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in childrenM Emonts, E L E de Bruijne, A H C Guimarães, et al.
Acta Gastro-Enterologica Belgica|March 22, 2018
Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumabH Peeters, E Louis, F Baert, et al.
Pageof 6